Cogent Biosciences (COGT)
(Delayed Data from NSDQ)
$8.58 USD
-0.31 (-3.49%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $8.57 -0.01 (-0.12%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Brokerage Reports
Cogent Biosciences, Inc. [COGT]
Reports for Purchase
Showing records 1 - 20 ( 131 total )
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
One Step Ahead; New Developments in Cancer Resistance
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
We Continue to View Bezuclastinib''s Results in the SUMMIT and PEAK Trials Favorably; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Key Takeaways for ASCO 2024; Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology -ASCO 2024 Abstract Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Bezu Playing Catch Up; Another Peek at the PEAK at ASCO
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
After a Disappointing Showing at ASH, Bezuclastinib Shows Signs of Promise Again; 2023 Financials; Raising PT to $19
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Bezuclastinib Currently in "Show Me" Position; Lowering PT to $13
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Bezu Falls from the SUMMIT; Downgrade to Neutral
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D